City of Hope | Strategic Alliance Partners

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.

Cancer Treatment Centers of America's comprehensive cancer centers in Chicago and Atlanta earned the 2021 Guardian of Excellence Award from Press Ganey as top performers in patient experience.

It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.

Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

The trial is the first in the world offering this City of Hope-developed investigational therapy to patients with the hope of one day improving survival for people with triple-negative breast cancer.

Katherine Poruk, MD, a board-certified and fellowship-trained surgical oncologist and researcher, is the latest addition to the Cancer Treatment Centers of America®, Atlanta, physician team.

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Corepoint Integration Engine chosen to Streamline Connectivity Across Care Teams, Affiliate Networks, and Cancer Community, Extending Access to World-class Care for Patients Everywhere.

The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

CTCA leverages new CMS Conditions of Participation notification requirements as opportunity for innovation

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.